

Datasheet for ABIN7179972  
**anti-RUNX1 antibody (Ser435)**



[Go to Product page](#)

2 Images

## Overview

|                      |                                      |
|----------------------|--------------------------------------|
| Quantity:            | 100 µL                               |
| Target:              | RUNX1                                |
| Binding Specificity: | Ser435                               |
| Reactivity:          | Human                                |
| Host:                | Rabbit                               |
| Clonality:           | Polyclonal                           |
| Conjugate:           | This RUNX1 antibody is un-conjugated |
| Application:         | Western Blotting (WB), ELISA         |

## Product Details

|                   |                                                                                                                       |
|-------------------|-----------------------------------------------------------------------------------------------------------------------|
| Immunogen:        | Synthesized non-phosphopeptide derived from Human AML1 around the phosphorylation site of serine 435 (S-N-S(p)-P-T).  |
| Isotype:          | IgG                                                                                                                   |
| Cross-Reactivity: | Human, Mouse                                                                                                          |
| Purification:     | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |

## Target Details

|                   |                                          |
|-------------------|------------------------------------------|
| Target:           | RUNX1                                    |
| Alternative Name: | RUNX1 ( <a href="#">RUNX1 Products</a> ) |

## Target Details

|             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Background: | <p>Background: CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits KAT6B-dependent transcriptional activation.</p> <p>Miyoshi H., Proc. Natl. Acad. Sci. U.S.A. 88:10431-10434(1991).</p> <p>Sacchi N., Genes Chromosomes Cancer 11:226-236(1994).</p> <p>Nucifora G., Blood 81:2728-2734(1993).</p> <p>Aliases: Acute myeloid leukemia 1 antibody, Acute myeloid leukemia 1 protein antibody, alpha subunit core binding factor antibody, AML 1 antibody, AML1 antibody, AML1 EVI 1 antibody, AML1 EVI 1 fusion protein antibody, Aml1 oncogene antibody, AMLCR 1 antibody, AMLCR1 antibody, CBF alpha 2 antibody, CBF-alpha-2 antibody, CBFA 2 antibody, CBFA2 antibody, Core binding factor alpha 2 subunit antibody, Core binding factor runt domain alpha subunit 2 antibody, Core-binding factor subunit alpha-2 antibody, EVI 1 antibody, EVI1 antibody, HGNC antibody, Oncogene AML 1 antibody, Oncogene AML-1 antibody, OTTHUMP00000108696 antibody, OTTHUMP00000108697 antibody, OTTHUMP00000108699 antibody, OTTHUMP00000108700 antibody, OTTHUMP00000108702 antibody, PEA2 alpha B antibody, PEA2-alpha B antibody, PEBP2 alpha B antibody, PEBP2-alpha B antibody, PEBP2A2 antibody, PEBP2aB antibody, Polyomavirus enhancer binding protein 2 alpha B subunit antibody, Polyomavirus enhancer-binding protein 2 alpha B subunit antibody, Run1 antibody, Runt related transcription factor 1 antibody, Runt-related transcription factor 1 antibody, RUNX 1 antibody, Runx1 antibody, RUNX1_HUMAN antibody, SL3 3 enhancer factor 1 alpha B subunit antibody, SL3-3 enhancer factor 1 alpha B subunit antibody, SL3/AKV core binding factor alpha B subunit antibody, SL3/AKV core-binding factor alpha B subunit antibody</p> |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|          |                        |
|----------|------------------------|
| UniProt: | <a href="#">Q01196</a> |
|----------|------------------------|


## Application Details

|                    |                       |
|--------------------|-----------------------|
| Application Notes: | WB:1:500-1:3000,      |
| Restrictions:      | For Research Use only |

Handling


|                    |                                                                                                                              |
|--------------------|------------------------------------------------------------------------------------------------------------------------------|
| Format:            | Liquid                                                                                                                       |
| Buffer:            | Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol. |
| Preservative:      | Sodium azide                                                                                                                 |
| Precaution of Use: | This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.       |
| Storage:           | -20 °C,-80 °C                                                                                                                |
| Storage Comment:   | Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.                                                                |

Images



**Western Blotting**

**Image 1.** Western blot analysis of extracts from 293 cells (Lane 2) and HeLa cells (Lane 3), using AML1 (Ab-435) antibody. The lane on the left is treated with synthesized peptide.



**Western Blotting**

**Image 2.** Western blot analysis of extracts from HepG2 cells, treated with PMA (125 ng/mL, 30 mins), using AML1 (Ab-435) antibody.